To support innovators in Africa, create an environment where African R&D thrives

Q+A with award-winning malaria researchers, Abdoulaye Djimdé & Isabella Oyier

Read next

Inside Cape Town International Airport in South Africa soon after the discovery of the Omicron variant of COVID and the imposition of many bans on travel from southern Africa.

Southern Africa: Last in line for vaccines, first in line for travel bans

Instead of reacting to the identification of the Omicron variant of COVID-19 with travel bans and fear, the world should be lauding southern African scientists, investing in their research capacity, and addressing vast inequities in vaccine distribution.
By Cheikh Oumar Seydi Senior Advisor, Africa, Bill & Melinda Gates Foundation
A long-lasting insecticide-treated mosquito bed net hangs in a woman’s home in Ifakara, Tanzania.

What will it take to outsmart malaria?

The extensive research and development behind the breakthrough new malaria vaccine is informing work on a new generation of complementary tools to control, prevent, and ultimately eradicate malaria.
By Philip Welkhoff Director, Malaria; Director, Institute for Disease Modeling, Bill & Melinda Gates Foundation
Workers in Abuja, Nigeria, scan a box containing vials of a COVID-19 vaccine procured through COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, March 2, 2021.

One year in: Extraordinary achievement, powerful momentum, and still a shortfall for the ACT-Accelerator

The world must redouble its efforts to ensure global equity in COVID-19 vaccines, tests, and therapies.
By Mark Suzman CEO, Board Member, Bill & Melinda Gates Foundation